Evidence map›Paper›PMID 38658307›Full record

ArticleVascular pharmacology2024

Corrigendum to "Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis" [Vascular Pharmacology 155 (2024) 107368].

Bandana Singh, Kui Cui, Shahram Eisa-Beygi, Bo Zhu, Douglas B Cowan, Jinjun Shi, Chris A Bashur, Da-Zhi Wang, Zhenguo Liu, Joyce Bischoff and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Bandana SinghVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Kui CuiVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Shahram Eisa-BeygiVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Bo ZhuVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Douglas B CowanVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Jinjun ShiDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Chris A BashurDepartment of Biomedical, Chemical Engineering and Science, Florida Institute of Technology, 150 West University Blvd., Melbourne, FL, USA.
Da-Zhi WangCenter for Regenerative Medicine, University of South Florida Health Heart Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
Zhenguo LiuDivision of Cardiovascular Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, USA.
Joyce BischoffVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Hong ChenVascular Biology Program, Department of Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA. Electronic address: hong.chen@childrens.harvard.edu.

Funding

Epsin in Angiogenesis and Vascular RemodelingR01HL093242 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHEN, HONG, WANG, DA-ZHI · 2009 to 2021
$7.3M
Molecular Mechanisms Controlling Lymphatic Vascular Function in Health and DiseaseR01HL133216 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, DIXON, JAMES BRANDON · 2016 to 2025
$6.7M
Molecular Regulation of AtherosclerosisR01HL146134 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, SRIVASTAVA, SANJAY · 2019 to 2022
$3.3M
CD45-mediated endothelial-to-mesenchymal transition in cardiovascular diseaseR01HL141853 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, WANG, DA-ZHI · 2020 to 2023
$3.3M
The role of signaling adaptor protein epsin in atherosclerosisR01HL156362 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, SHI, JINJUN · 2021 to 2024
$3.1M
The Role of Adaptor Protein Disabled-2 in Maintaining Endothelial Cell Function in AtherosclerosisR01HL162367 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, SHI, JINJUN · 2022 to 2025
$3.0M
Molecular Mechanisms Governing Vascular Cell Function and Phenotype in Health and DiseaseR01HL158097 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, CHEN, YABING · 2021 to 2024
$3.0M
Role of PXR in drug-elicited cardiovascular diseaseR01HL167206 · NHLBI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Hong Chen, Changcheng Zhou · 2023 to 2026
$2.8M
Novel role of Foxc2 in regulating metabolic diseaseK99HL171947 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CUI, KUI · 2024 to 2025
$251k
BLRD VA I01 BX004426NHLBI NIH HHS K99 HL171947NHLBI NIH HHS R01 HL093242NHLBI NIH HHS R01 HL133216NHLBI NIH HHS R01 HL141853NHLBI NIH HHS R01 HL146134NHLBI NIH HHS R01 HL156362NHLBI NIH HHS R01 HL158097NHLBI NIH HHS R01 HL162367NHLBI NIH HHS R01 HL167206
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38658307
PMCPMC11304823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.